Document is current

Article History

Received: 16 January 2025

Accepted: 24 August 2025

First Online: 12 September 2025

Change Date: 27 October 2025

Change Type: Update

Change Details: Original article has been corrected to update supplementary files.

Declarations

:

: Yoshinari Yasuda reports payment or honoraria from Kowa Co. Ltd., Nippon Boehringer Ingelheim, AstraZeneca, Ono Pharmaceutical Co., Ltd. Yusuke Suzuki reports research fundings from Moderna TX, Inc., Travere Therapeutics, Inc., Novartis Pharmaceuticals, Chinook Therapeutics, Inc., ARGENX, Aurinia Pharmaceuticals, Inc., Pfizer, Inc., and Rona Bioscience, consulting fees from Otsuka Pharmaceutical (Visterra), Novartis Pharmaceuticals, Chinook Therapeutics, ARGENX, BioCryst Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Renalys, Alpine, and George Clinical, and payment or honoraria from Kyowa Kirin Co., Ltd, Novartis Pharmaceuticals, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical Co., Ltd., DAIICHI SANKYO, AstraZeneca, Boehringer Ingelheim, Chinook Therapeutics, Inc. The other authors have declared no conflicts of interest.

: This study was performed in accordance with the tenets of the Declaration of Helsinki and was approved by the ethics committee of Showa Medical University Hospital (approval number: 2323).

: The requirement for written, informed consent was waived because de-identified retrospective data were used.